Physician profile
Madhurima Adulla
NPI 1073523247
$1,292.93
in general payments reported to CMS, 2019-2025
21 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2024: $258 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $424.67 | 2021 | |
| Amgen INC. | $178.50 | 2024-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $103.74 | 2024-2025 | |
| Ucb, INC. | $102.14 | 2024-2025 | Bimzelx, Cimzia |
| Calliditas Therapeutics US INC. | $68.04 | 2024-2025 | Tarpeyo |
| Janssen Biotech, INC. | $43.96 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $43.10 | 2024-2025 | Orencia |
| Genzyme Corporation | $42.79 | 2025 | |
| Apellis Pharmaceuticals, INC. | $40.96 | 2025 | Empaveli |
| Otsuka America Pharmaceutical, INC. | $26.26 | 2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $24.74 | 2025 | Farxiga |
| Esperion Therapeutics, INC. | $24.11 | 2025 | Nexletol |
| Travere Therapeutics, INC. | $23.50 | 2025 | |
| Baxter Healthcare | $23.13 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Amphastar Pharmaceuticals, INC. | $20.99 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.22 | 2025 | Gvoke Hypopen |
| Ani Pharmaceuticals, INC. | $18.89 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $18.03 | 2025 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $15.88 | 2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $14.98 | 2024 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $14.30 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhurima Adulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.